| Online-Ressource |
Verfasst von: | Robert, Caroline [VerfasserIn]  |
| Long, Georgina V. [VerfasserIn]  |
| Brady, Benjamin [VerfasserIn]  |
| Dutriaux, Caroline [VerfasserIn]  |
| Di Giacomo, Anna Maria [VerfasserIn]  |
| Mortier, Laurent [VerfasserIn]  |
| Rutkowski, Piotr [VerfasserIn]  |
| Hassel, Jessica C. [VerfasserIn]  |
| McNeil, Catriona M. [VerfasserIn]  |
| Kalinka, Ewa Anna [VerfasserIn]  |
| Lebbé, Céleste [VerfasserIn]  |
| Charles, Julie [VerfasserIn]  |
| Hernberg, Micaela M. [VerfasserIn]  |
| Savage, Kerry J. [VerfasserIn]  |
| Chiarion-Sileni, Vanna [VerfasserIn]  |
| Mihalcioiu, Catalin [VerfasserIn]  |
| Mauch, Cornelia [VerfasserIn]  |
| Arance, Ana [VerfasserIn]  |
| Cognetti, Francesco [VerfasserIn]  |
| Ny, Lars [VerfasserIn]  |
| Schmidt, Henrik [VerfasserIn]  |
| Schadendorf, Dirk [VerfasserIn]  |
| Gogas, Helen [VerfasserIn]  |
| Zoco, Jesús [VerfasserIn]  |
| Re, Sandra [VerfasserIn]  |
| Ascierto, Paolo A. [VerfasserIn]  |
| Atkinson, Victoria [VerfasserIn]  |
Titel: | Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma |
Verf.angabe: | Caroline Robert, MD, PhD; Georgina V. Long, PhD, MBBS; Benjamin Brady, MD; Caroline Dutriaux, MD, PhD; Anna Maria Di Giacomo, MD, PhD; Laurent Mortier, MD, PhD; Piotr Rutkowski, MD, PhD; Jessica C. Hassel, MD; Catriona M. McNeil, MD; Ewa Anna Kalinka, MD; Céleste Lebbé, MD; Julie Charles, MD, PhD; Micaela M. Hernberg, MD; Kerry J. Savage, MSc, MD; Vanna Chiarion-Sileni, MD; Catalin Mihalcioiu, MD; Cornelia Mauch, MD, PhD; Ana Arance, MD, PhD; Francesco Cognetti, MD; Lars Ny, MD; Henrik Schmidt, MD; Dirk Schadendorf, MD; Helen Gogas, MD, PhD; Jesús Zoco, MS; Sandra Re, MD,MB; Paolo A. Ascierto, MD; and Victoria Atkinson, MD |
E-Jahr: | 2020 |
Jahr: | September 30, 2020 |
Umfang: | 12 S. |
Fussnoten: | Gesehen am 29.01.2021 |
Titel Quelle: | Enthalten in: Journal of clinical oncology |
Ort Quelle: | Alexandria, Va. : American Society of Clinical Oncology, 1983 |
Jahr Quelle: | 2020 |
Band/Heft Quelle: | 38(2020), 33, Seite 3937-3946 |
ISSN Quelle: | 1527-7755 |
Abstract: | PURPOSEThe CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.PATIENTS AND METHODSIn this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m2 every 3 weeks. The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.RESULTSPatients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-up, 32.0 months for nivolumab and 10.9 months for dacarbazine). Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively. Five-year OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolumab (n = 37). ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively. Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis. Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free. Safety analyses were similar to the 3-year report.CONCLUSIONResults from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy. Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies. |
DOI: | doi:10.1200/JCO.20.00995 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1200/JCO.20.00995 |
| Volltext: https://ascopubs.org/doi/10.1200/JCO.20.00995 |
| DOI: https://doi.org/10.1200/JCO.20.00995 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1745984518 |
Verknüpfungen: | → Zeitschrift |
Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma / Robert, Caroline [VerfasserIn]; September 30, 2020 (Online-Ressource)